Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy

Maturitas

Volumn 59, Issue 4, 2008, Pages 387-393

  Markovitch, O ^a   Tepper, R ^a   Fishman, A ^a   Aviram, R ^a   Cohen, Ilan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Discontinuation; Follow up; Postmenopause; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL EVALUATION; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG WITHDRAWAL; ENDOMETRIUM BIOPSY; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD; POSTMENOPAUSE; STATISTICAL SIGNIFICANCE; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION;

AGED; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 44349085910     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.04.001     Document Type: Article

References (34)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339 (1992) 1-71 71-85
2. Cohen I., Rosen D.J.D., Shapira J., et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynecol 100 (1993) 567-570
3. Cohen I., Rosen D.J.D., Shapira J., et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and non-treated asymptomatic breast cancer patients. Gynecol Oncol 52 (1994) 185-190
4. Cohen I., Tepper R., Rosen D.J.D., et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 55 (1994) 138-143
5. Borenstein J., Ausllender R., Pascal B., et al. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 39 (1994) 674-678
6. Cohen I., Perel E., Tepper R., et al. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients. Breast Cancer Res Treat 53 (1999) 255-262
7. Cohen I., Perel E., Flex D., et al. Endometrial pathologies in postmenopausal tamoxifen treatment: comparison between gynaecological symptomatic and gynaecological asymptomatic breast cancer patients. J Clin Pathol 52 (1999) 278-282
8. Cohen I., Azaria R., Shapira J., et al. The significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer 94 (2002) 3101-3106
9. Fornander T., Cedermak B., Mattson A., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 (1989) 117-120
10. Andersson M., Storm H., and Mouridsen T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83 (1991) 1013-1017
11. van Leeuwen F.E., Benraadt J., Coebergh J.W.W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452
12. Deligdisch L., Kalir N., Cohen C.J., et al. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 78 (2000) 181-186
13. Mignotte H., Lasset C., Bonadona V., et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 76 (1998) 325-330
14. Cohen I., Bernheim J., Azaria R., et al. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 75 (1999) 136-141
15. Magriples U., Naftolin F., Schwartz P.E., et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11 (1993) 485-490
16. Rutquist L.E., Johnson H., Signomaklo T., et al. Adjuvant tamoxifen therapy for early breast cancer and second primary cancer. J Natl Cancer Inst 87 (1995) 645-651
17. Curtis R.E., Boice J.D., Shriner D.A., et al. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88 (1996) 832-834
18. Sasco A.J., Chaplin G., Amoros E., et al. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 7 (1996) 9-13
19. Bernstein L., Deapen D., Cerhan J.R., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91 (1999) 1654-1662
20. Bergman L., Beelen M.L.R., Gallee M.P.W., et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356 (2000) 881-887
21. McCluggage W.G., McManus D.T., Lioe T.F., et al. Uterine carcinosarcoma in association with tamoxifen therapy. Br J Obstet Gynaecol 104 (1997) 748-750
22. Bouchardy C., Verkooijen H.M., and Fioretta G. Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen. J Clin Oncol 20 (2002) 4403-4409
23. Swerdlow A.J., and Jones M.E. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97 (2005) 375-384
24. Hachisuga T., Saito T., Kigawa J., et al. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for breast cancers. Gynecol Oncol 95 (2004) 139-144
25. Ferguson S.E., Solow R.A., Amsterdam A., et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 101 (2005) 322-326
26. Markovitch O., Tepper R., Fishman A., et al. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients. Breast Cancer Res Treat 101 (2007) 185-190
27. Berliere M., Galant C., Charles A., et al. Endometrial evaluation is a very important tool in the management of breast cancer patients. Eur J Cancer 6 Suppl. (2002) S67-S68
28. Love C.D.B., Muir B.B., Scrimgeour J.B., et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17 (1999) 2050-2054
29. Cohen I., Beyth Y., Azaria R., et al. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. Br J Obstet Gynecol 107 (2000) 1083-1087
30. Menada M.V., Papadia A., Lorenzi P., et al. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaecol Oncol 25 (2004) 321-323
31. Fishman M., Boda M., Sheiner E., et al. Changes in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy. J Ultrasound Med 25 (2006) 469-473
32. Gerber B., Krause A., Muller H., et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 18 (2000) 3464-3470
33. Nahari K., Tepper R., Beyth Y., et al. Long-term transvaginal endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment. Gynecol Oncol 74 (1999) 222-226
34. Decensi A., Fontana V., Bruno S., et al. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 14 (1996) 434-440